Neuralink updates

Two Years of Telepathy
Announcing 21 Neuralink participants.

Welcome, David McMullen!
We’re thrilled to welcome David McMullen to Neuralink.

Neuralink Overview, Fall 2025 (opens in a new tab)
DJ and our recruiting team visited several schools to provide an overview of Neuralink, including recent progress updates and an outline for the company’s path ahead.

GB-PRIME Study Launch
We are excited to announce that we are launching the GB-PRIME study across two sites in Great Britain!

Neuralink Update, Summer 2025 (opens in a new tab)
A technical progress update from the Neuralink team.

Neuralink raises $650M Series E
Our $650M Series E will expand patient access to our technology and push the boundaries of what’s possible with brain interfaces.

Neuralink Receives Breakthrough Device Designation for Speech
We've received Breakthrough Device Designation from the FDA to help restore communication for individuals with severe speech impairment.

A Year of Telepathy
Over the past year, three people with paralysis have received Neuralink implants. This blog post explores how each person is using Telepathy in everyday life.

CONVOY Study Launch
We’re excited to announce the launch of a new feasibility trial to extend BCI control using the N1 Implant to an investigational assistive robotic arm.

CAN-PRIME Study Launch
We are excited to announce that we have received approval from Health Canada to launch the CAN-PRIME Study, our first international trial!

Neuralink Receives Breakthrough Device Designation for Blindsight
We are excited to announce that we have received Breakthrough Device Designation from the FDA for Blindsight! For individuals with vision impairment.

PRIME Study Progress Update — Second Participant
Our technology is enabling our second PRIME Study participant to play video games and use CAD software. This post shares updates on his experience.

Neuralink Update (opens in a new tab)
The Neuralink team shares an update on the progress of the first Neuralink study participant and changes made in advance of the second participant.

PRIME Study Progress Update — User Experience
We’ve just passed 100 days since the first participant in our clinical trial received his Neuralink implant. Read our latest progress update.

PRIME Study Progress Update
In January, we conducted the first human implantation of our brain-computer interface. This blog post shares a high-level snapshot of where we are as a company.

Neuralink’s Patient Registry Opens to Canada
In Neuralink's first international expansion, our Patient Registry is now accepting applications from Canadian residents.

Understanding Preclinical Research at Neuralink
Become acquainted with the Preclinical Team, which is responsible for the design, conduct, documentation, analysis, and reporting of preclinical studies.

Neuralink’s First-in-Human Clinical Trial is Open for Recruitment
We are happy to announce that we've received approval to begin recruitment for our first-in-human trial at our first hospital site.

Neuralink Raises $280M Series D
We’re happy to announce our $280M Series D round led by Founders Fund. We’re extremely excited about this next chapter at Neuralink.

The Role of the Institutional Animal Care and Use Committee
We explore the functions of Neuralink’s Institutional Animal Care and Use Committee (IACUC) and its role in promoting refinement, reduction, and replacement.

Environmental Enrichment
In our second blog on refinement, we highlight our methodology to ensure that we provide an enriching environment and experience to animals within our care.

Announcing Neuralink's Patient Registry
We’ve launched a Patient Registry to learn more about individuals who may be interested in enrolling in future Neuralink clinical trials.

Husbandry Refinement
The first episode of our Refinement Series will look at how we evaluate the well-being of an animal as it pertains to housing, food, and water.

Neuralink Show and Tell, Fall 2022 (opens in a new tab)
A technical progress update from the Neuralink team.

Championing the 3 Rs
We hope you will take this opportunity to learn alongside us as we dive into the complex world of ensuring animal well-being in a research setting.

Neuralink's Commitment to Animal Welfare
Animals at Neuralink are respected and honored by our team. In this blog post, we provide an accurate statement of Neuralink’s commitment to animal welfare.

Series C Funding Round Announcement
Neuralink is pleased to announce our Series C funding round of $205 million. Neuralink is developing brain-computer interfaces to treat brain related ailments.

Neuralink Progress Update, Summer 2020 (opens in a new tab)
A technical progress update from the Neuralink team.

Neuralink Launch Event (opens in a new tab)
Introducing Neuralink.
